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Abstract
Background: Low back pain and its associated incapacitating effects constitute an important healthcare and socioeconomic
problem, as well as being one of the main causes of disability among adults of working age. The prevalence of non-specific low
back pain is very high among the general population, and 60–70% of adults are believed to have suffered this problem at some
time. Nevertheless, few randomised clinical trials have been made of the efficacy and efficiency of acupuncture with respect to
acute low back pain. The present study is intended to assess the efficacy of acupuncture for acute low back pain in terms of the
improvement reported on the Roland Morris Questionnaire (RMQ) on low back pain incapacity, to estimate the specific and
non-specific effects produced by the technique, and to carry out a cost-effectiveness analysis.
Methods/Design: Randomised four-branch controlled multicentre prospective study made to compare semi-standardised real
acupuncture, sham acupuncture (acupuncture at non-specific points), placebo acupuncture and conventional treatment. The
patients are blinded to the real, sham and placebo acupuncture treatments. Patients in the sample present symptoms of non
specific acute low back pain, with a case history of 2 weeks or less, and will be selected from working-age patients, whether in
paid employment or not, referred by General Practitioners from Primary Healthcare Clinics to the four clinics participating in
this study.
In order to assess the primary and secondary result measures, the patients will be requested to fill in a questionnaire before the
randomisation and again at 3, 12 and 48 weeks after starting the treatment. The primary result measure will be the clinical
relevant improvement (CRI) at 3 weeks after randomisation. We define CRI as a reduction of 35% or more in the RMQ results.
Discussion: This study is intended to obtain further evidence on the effectiveness of acupuncture on acute low back pain and
to isolate the specific and non-specific effects of the treatment.
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Background
Low back pain and its associated incapacitating effects
constitute an important healthcare and socioeconomic
problem, as well as being one of the main causes of disa-
bility among adults of working age [1]. The prevalence of
non-specific low back pain is very high among the general
population, and 60–70% of adults are believed to have
suffered this problem at some time [2]. Acute low back
pain is of non-specific musculo-skeletal origin in 95% of
cases [3] and the process is normally self-limiting. How-
ever, between 2% and 24% of cases last over three
months[4,5]. In Spain, absence from work because of
back pain lasts an average of almost 22 days and costs, on
average, 1260 euros per worker, representing 19–25% of
the total expense of temporary incapacity benefit paid. An
average of 55,388 work days are lost every year because of
back pain. By sectors, the highest number of days lost for
this reason correspond to industry (37.1%), the service
sector (29.9%), construction (27.5%) and agriculture
(5.5%). About 90% of patients affected by non-specific
back pain resume work within 6 months [6].
Apart from the standard distinction between the acute
nature of low back pain (less than 6 weeks' duration) [1],
subacute (between 6 weeks and 3 months) and chronic
(more than 3 months), the various texts on the question
have stressed the need to distinguish between specific and
non-specific low back pain. There is generalised agree-
ment that the clinical history and the physical examina-
tion should be sufficiently detailed to enable a diagnostic
orientation and to flag the existence, if any, of the so-
called red flags, such as fractures, tumors, infections or
inflammatory rheumatic illnesses such as ankylosing
spondylitis, as well as factors that may promote the
chronic aspect of the process, the so-called yellow flags, or
factors that are individual and work-related [3].
The conventional standard treatment (CT) for non-spe-
cific acute low back pain is to prescribe medicaments such
as non-opiate analgesics, non-steroidal anti-inflamma-
tory drugs (NSAIDs), myorelaxants and opioides. The evi-
dence obtained from the 51 studies included in a
systematic review [7] suggests that NSAIDs are effective for
the short term relief of symptoms among patients with
acute low back pain, but that there does not seem to be
any one specific type of NSAID that is clearly more effec-
tive than any other. Myorelaxants are effective in treating
non-specific low back pain, but their adverse side effects
mean they must be used with caution. What is needed are
trials to determine whether myorelaxants are more effec-
tive than analgesics or NSAIDs [8]. It has yet to proven
whether benefit is to be derived from physical fitness pro-
grammes in reducing work time lost and in increasing the
functional state of patients who suffer from acute low
back pain [9].
Few randomised clinical trials (RCT) have been made to
assess the efficacy of acupuncture in treating acute low
back pain. A recent review by Cochrane Collaboration
selected just three studies for analysis, and was unable to
draw conclusive conclusions because of the small size of
the samples and the poor methodological characteristics
of the studies examined [10]. A later review [11] that
extended the search area to August 2004 was no more con-
clusive as regards acute low back pain.
The different RCT that have been made to investigate the
efficacy of acupuncture tend to use different types of con-
trol group, with the following being the most commonly
adopted: 1) sham acupuncture, which has various possi-
ble modes, including: A) performing acupuncture at
points that are not considered to be acupuncture points,
to a depth of less than 2 mm and without applying any
stimulus to these points; B) performing acupuncture at
points that are considered to be acupuncture points but
which are not specifically recommended for treating the
pathology in question; 2) placebo acupuncture, which
consists of using retractable telescopic needles resting on
an adhesive base that exercises a pressure on the skin with-
out actually puncturing it; 3) alternatively, in situations in
which the patient cannot observe the technique directly
(e.g. points on the patient's back, with the patient lying
face down), what is known is acupuncture simulation,
which consists of pressing with a blunt object (or a
pointed one such as a toothpick), on the surface of the
skin, making the patient believe that a needle has been
inserted.
Complex non-pharmacological treatments, such as acu-
puncture, are complicated to evaluate because it is diffi-
cult to isolate the characteristic or specific effects of the
technique from the non-specific ones (i.e. the placebo
effects) [12]. One problem that arises in investigating the
problem is that of choosing appropriate placebo controls
if the goal is to evaluate specific effects [13]. For example,
techniques that involve the puncture/penetration of the
skin and which present the lowest probability of being
discovered, and thus are considered the best in terms of
the degree of blinding achieved, may cause a significant
physiological response [14]. Various reviews have
described a negative correlation between the quality of the
study and the results obtained (i.e. the highest quality
studies tend to produce negative results more often [15-
17]. This finding should be interpreted with caution
because many revisions include trials with non-compara-
ble control groups, such as a waiting list, or a group that
received no treatment at all, or different types of placebo
(such as those listed above) and a variety of active control
groups.BMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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Studies in which the results are compared for different
control groups with different types of placebo may make
things clearer, in separating non-specific or contextual
effects from those derived specifically from the applica-
tion of acupuncture.
In the light of these considerations, we designed a ran-
domised controlled study of patients with non-specific
acute low back pain in order to investigate the efficacy of
traditional acupuncture in comparison with three types of
control group (sham acupuncture, placebo acupuncture
and conventional treatment) with the objectives of isolat-
ing the effects attributable to each of these treatments and
of separating the specific from the non-specific ones. We
also sought to assess the evolution of the illness, using a
system to measure the patient's degree of incapacity, the
intensity of the pain suffered, the quality of life, the dura-
tion of the absence from work, the consumption of anal-
gesic and anti-inflammatory medication and the potential
effect of the factors that were considered to be predictors




Randomised four-branch controlled multicentre prospec-
tive study made to compare semi-standardised real acu-
puncture (Group A), sham acupuncture (acupuncture at
non-specific points) (Group B), placebo acupuncture
(Group C) and solely the conventional treatment recom-
mended in guides to clinical practice [19,20] (Group D).
The patients are blinded to the real, false and placebo acu-
puncture treatments. The evaluation of the patients and
the analysis of the results will be carried out by profession-
als who are blinded to the assignment of patients to the
various groups.
Study subjects
Persons of working age who attend for treatment, for the
first time in at least six months, reporting symptoms of
non-specific acute low back pain to their General Practi-
tioner (GP) at one of the Primary Healthcare Clinics par-
ticipating in the study and belonging to the Andalusian
Public Health System (Pain Treatment Unit at the Dos
Hermanas Healthcare Clinic in Sevilla, Rehabilitation
Service at the Specialised High Resolution Centre in
Malaga, the Acupuncture Unit of the Málaga Health Dis-
trict and the San Andrés-Torcal Healthcare Clinic in
Málaga). The patients will be informed as follows: "This
Centre is engaged in a study intended to evaluate and
quantify the effects of conventional treatment, in isola-
tion, compared to the same treatment applied in combi-
nation with two types of acupuncture, one of these being
similar to traditional Chinese acupuncture, and the other
not following the same principles. In addition, there will
be a control group which will be given placebo acupunc-
ture (in addition to the conventional treatment). I have
been told that I may be included in a random fashion (by
means of a draw) in one of the four treatment groups".
The patients will also be informed of the possible risks
associated with the different types of acupuncture (infec-
tion, fainting, bruising) and that they may end their par-
ticipation in the study at any time without suffering any
kind of penalisation or loss of benefits to which they
would otherwise be entitled.
Selection criteria
▪ Criteria for inclusion:
• Signature of informed consent form;
• New episode of non-specific acute low back pain of less
than 2 weeks' evolution, with or without irradiation
(diagnosed by clinical history and physical examination).
We define 'new' as the first episode in at least the last 6
months.
• Patient of working age (whether in paid employment or
not), either occupationally active or absent from work
because of back pain;
• No previous treatment with acupuncture (in order to
minimise the possibility of patients being able to distin-
guish the real acupuncture treatment from the various
control modes).
▪ Criteria for exclusion, one or more of the following
symptoms or illnesses:
• More than one absence from work because of back pain
within a period of 6 months (in order to eliminate possi-
ble mercenary motives);
• The presence of alarm signs that suggest the protrusion
or prolapse of one or more intervertebral disks with con-
current neurologic symptoms, infectious spondylopathy,
previous surgery affecting the spine, low back pain caused
by inflammatory illness, whether malign or autoimmune,
congenital deformities of the spine except for slight scho-
liosis or lordosis, vertebral fractures, stenosis of the spinal
canal, spondylolysis or spondylolisthesis ;
• Contraindications for acupuncture such as extensive
skin disorders, treatment with anticoagulants, or preg-
nancy;
• Incapacity to complete the questionnaires or to answer
the questions of the assessor.BMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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Study sequence Figure 1
Study sequenceBMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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Ethical criteria
The ethical validity of this study has been analysed by the
Andalusian Regional Committee for Clinical Trials, after
approval by the Research Committee at each of the health-
care clinics concerned. In designing this study, due atten-
tion was paid to the fundamental principles established in
the Helsinki Declaration, as restated in Tokyo 2004, at the
Convention of the Council of Europe concerning human
rights and biomedicine, as well as the requirements set
out under Spanish law with respect to biomedical
research, the protection of personal data and bioethics. All
the patients must sign a statement of informed consent to
the clinical procedures involved in the study. During its
development, we shall carry out the audits required by the
Research and Ethics Reference Committee at each clinic,
in addition to any external audits (of the research fund
provider) that may be required.
Randomisation
Sampling will be by consecutive selection according to cri-
teria of inclusion-exclusion during a period of 12 months
until the required sample numbers are achieved. The ran-
domised allocation to the four branches of the study will
be performed using a specialised computer program for
this purpose (EpiDat v 3.0) at a central location (Univer-
sity of Sevilla, School of Psychology, Department of Social
Psychology), following a 1:1:1:1 pattern (true acupunc-
ture: sham acupuncture: placebo acupuncture: conven-
tional treatment), with one sequence for each clinic, in
blocks of eight. Neither the clinics nor the doctors partic-
ipating in the study will be involved in the randomisation
process. The patients who meet the criteria for inclusion
and who give their written informed consent will be
included in the study. Following inclusion, the patient's
GP will contact the randomisation centre, where the
patient will be registered.
Participating clinics and doctors
The patients will be referred to one of the four reference
clinics for the baseline assessment to be performed, after
confirmation, on the referral form provided, that the cri-
teria for inclusion are met and that conventional treat-
ment has been prescribed by the corresponding GP. The
four clinics within the Andalusian Public Health System
that are included in the study are:
1. Pain Treatment Unit at the Dos Hermanas "A" Health
Centre (Sevilla)
2. Rehabilitation Service at the Specialised High Resolu-
tion Clinic (Málaga)
3. Acupuncture Unit of the Málaga Healthcare District
(Málaga)
4. San Andrés-Torcal Health Centre (Málaga)
At these clinics, the baseline assessment will be carried out
by independent assessors who will explain the procedure
and invite the patients to give their informed written con-
sent and to fill in a set of self-report questionnaires. Fol-
lowing this, they will enter the treatment room where the
doctors responsible for the treatment will make an assess-
ment according to the principles of traditional Chinese
medicine (TCM). They will then contact the Randomisa-
tion Centre to receive the patient's assignment to one of
the study groups and, in the case of those belonging to
Group B, the randomised sequence of points. Those
patients assigned to Groups A, B and C will be treated with
the corresponding acupuncture technique (true, sham or
placebo), always by the same doctor. The true, sham and
placebo acupuncture treatments will be blinded to the
patient and the assessor, but this cannot be done for the
doctor who must apply the treatment. To maximise the
blinding of the participants, we shall only include patients
who have no previous experience of acupuncture, so that
they will be unable to compare this treatment with earlier
ones; moreover, contact between participants in the study
will be restricted. At the end of the treatment, data will be
compiled to determine the effectiveness of the blinding.
The sequence to be followed in the study is set out in Fig-
ure 1. The doctors who will perform the different treat-
ments have all received at least 700 hours' training and
have an average experience of 8.5 years in the field.
Treatment details
The true, sham and placebo acupuncture groups will
receive a total of five acupuncture sessions (three in the
first week and two in the second), using the technique and
the acupuncture points described below. The disposable
sterile needles are manufactured by Cloud & Dragaon
Radical Device Co., Ltd (Wujiang, China) according to EU
standards and are imported by Acupuncture-Shop, Store-
gade 58, 6800 Vade (Denmark). Any adverse reactions or
collateral effects will be recorded in the Data Record Book
(DRB) with a detailed explanation of their type and the
dates on which they occurred.
It is well known that the expectations of the person
administering the technique play an important role,
whether the treatment is merely a placebo or genuine, and
that an enthusiastic, positive and empathetic attitude rein-
forces the therapeutic benefits [21]. Therefore, the practi-
tioners who participate in this study will be trained in the
different procedures to be employed in order to make
them more at ease in the application of the three tech-
niques specified for this study, and so that their attitude
shall be as identical as possible in all cases. For the same
reasons, the treatment time devoted to the patients
assigned to each of the groups (A, B and C) must be iden-BMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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tical, as is also the case for the pre- and post-session assess-
ments. We will take the precaution of asking the patients
to attend at different times, to prevent them from
exchanging opinions and telling each other of their expe-
rience. The fulfilment of the protocol will be carefully con-
trolled throughout the duration of the study.
A) True acupuncture (TA)
Conventional treatment (CT) + semi-standardised acu-
puncture according to the characteristics of the pain.
When the principles of TCM are observed, acupuncture is
an individualised therapy. In this study, we designed a
flexible, semi-standardised treatment protocol, similar to
that used in other studies [22,23], by selecting a group of
basic points (BP) that are predefined to be applied in
every case, and other, specific points (SP) determined
according to the main characteristics of the low back pain
suffered by the patient, but allowing the participating doc-
tors the freedom to add individualised points (IP) as
advised by their clinical experience or in the light of an
individual syndrome, according to the diagnostic princi-
ples of TCM. The predefined BP have been carefully
selected by a process of consensus with experts from the
two Spanish acupuncture societies, taking into account
the principles of TCM. The main reason for choosing a
semi-standardised treatment is to promote transparency
and a certain degree of replicability without sacrificing the
aspect of individualisation.
The doctors responsible for applying the treatment will
insert a sterile, disposable filiform acupuncture needle of
gauge 25 mm × 0.25 mm, or of 40 mm × 0.25 mm,
depending on the zone to be punctured, with the aid of a
guide tube, at each of the points indicated below, after
having disinfected the skin and with the patient lying face
down or on his/her side. The puncture will be perpendic-
ular, except in the cases described otherwise, to a depth of
0.5–1 distance (the measurement unit in acupuncture is
the  cun, the equivalent to the width of the patient's
thumb) The insertion is followed by stimulation using
broad bidirectional rotation movements of the sleeve of
the needle in order to produce Deqi, which is commonly
described as a radiated sensation. The needle is main-
tained in place for 20 minutes, and rotated for one minute
every five minutes (i.e. four times per session). After the
BP and the SP have been punctured, Xingzhen manipula-
tion (dynamic puncture) will be performed; this consists
of asking the patient to flex, extend and rotate the waist,
always to the degree that the pain suffered allows, while
the above-described manipulation is carried out.
▪ Obligatory BP: N-UE-19 (Yaotongxue), ipsilateral
▪ SP, according to the location of the low back pain:
• Dumai: Houxi SI-3, Shenmai BL-62 (laterality depending
on the type), Renzhong GV-26
• Zutaiyang: Yanglao SI-6, Kunlun BL-60, Zanzhu BL-2 ipsi-
lateral
• Zushaoyang and Daimai: Waiguan TE-5, Zulinqi GB-41,
Yanglingquan GB-34
▪ IP: a maximum of four points (unilateral and bilateral)
following the criteria of the doctor applying the treatment,
and on the basis of the diagnosis previously made. These
points will be recorded in the DRB.
B) Sham acupuncture (SA)
CT + acupuncture at points considered non-specific for
the complaint being studied [24], selected in a random
fashion. This technique has been employed as a control
placebo in non pain-related situations. The choice of this
method for our study is based on the well known physio-
logical activity of any acupuncture stimulus, namely the
production of a certain degree of analgesia by nociceptive
inhibition at the rear medullary horn, and even at higher
levels, particularly in the brainstem, a phenomenon
known as diffuse noxious inhibitory control (DNIC)
[25,26]. This technique is associated with a high degree of
credibility but, strictly speaking, it should not be consid-
ered a placebo. It shares with real acupuncture the non-
specific effects such as the time required, the physical con-
tact between patient and doctor, the patient's expectations
and the non-specific analgesic phenomena of the punc-
ture. The only difference between this and real acupunc-
ture is that the points to be selected are not ones that are
specifically recognised for the treatment of acute low back
pain.
The technique employed will not vary in any way from
that employed for Group A. When the patient is assigned
to Group B, the randomising centre will send a random
sequence with four pairs of points that are coded in its
database as "non specific" and these will be used in each
of the five sessions corresponding to the treatment. These
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▪ Zuqiaoyin GB-44
C) Placebo acupuncture (PA)
CT + placebo acupuncture (pressure in the lumbar
region), leading the patient to believe real acupuncture is
being applied [27,28]. This technique consists of applying
momentary pressure with a semi-blunted needle fitted
within a plastic is placed over one of the eight points
described below, after disinfection of the skin and with
the patient adopting a face-down or lateral position. This
technique has been found to be indistinguishable from
true acupuncture among patients who suffer acute low
back pain and who have never previously been treated
with acupuncture [29] and among patients with dental
pain [28]. It shares with real acupuncture the non-specific
effects of the latter, such as the time employed in the treat-
ment, the physical contact between patient and doctor,
and the patient's expectations, but it does not provide the
non-specific effects of the puncture that are described for
Group B. The patient must remain in a face-down or lat-
eral position for the 20 minutes of the session so that the
placebo technique may remain undiscovered. Every five
minutes, the doctor responsible for the treatment will
repeat the above-described activity over the points in
question. For each point, the doctor must open a new,
sealed pack containing the sterile needle, to reinforce the
credibility of the procedure.
▪ P1: located bilaterally at 1 cun from the L1 spinous apo-
physis
▪ P2: located bilaterally at 1 cun from the L2 spinous apo-
physis
▪ P3: located bilaterally at 1 cun from the L3 spinous apo-
physis
▪ P4: located bilaterally at 1 cun from the L4 spinous apo-
physis
D) Conventional treatment (CT)
These patients will be assessed in the same way as Groups
A, B and C, according to the principles of TCM, after
which their inclusion in the conventional treatment
group will be explained to them. For all the groups, this
treatment will be prescribed and controlled by the corre-
sponding GP. The patients will be asked to return to the
clinic after three weeks for a final assessment to be made.
Agreement will be reached with the GPs participating in
the study concerning the treatment protocol, as set out in
the guidelines to Clinical Practice and Teaching Materials
published by the Catalan Health Institute [19] and by the
European Group for the Management of Acute Non-spe-
cific Low Back Pain in Primary Care (COST B13) [20]. The
guidelines will be identical for all the patients entering the
study, as follows:
▪ The patient will be informed about his/her situation,
seeking to present it as a non-dramatic case.
▪ The patient will be recommended to avoid remaining in
bed and to keep as active as possible.
▪ Recommendations will be made concerning the appear-
ance of warning signals.
▪ The agreement reached is that the following drugs may
be prescribed:
• Paracetamol (500 - 650 mg/6 - 8 h (maximum 4 gr/
day))
• Ibuprofene (400 - 600 mg/8 h)
• Diclophenac (50 mg/8 - 12 h)
• Ciclobenzaprin (10 mg/6 - 8 h (max. 1 week))
Consumption of these drugs will be recorded, together
with the pattern of use, in the patient's referral form.
Variables
Selection of variables
To evaluate the primary and secondary result measures,
the patients will be asked to fill in a series of question-
naires containing the details described below, before ran-
domisation and also after weeks 3, 12 and 48 after starting
the treatment. All the clinical variables will be evaluated
and analysed by independent observers. The primary
result measure is the clinical relevant improvement
(CRI) of the lumbar complaint at three weeks after ran-
domisation. We define CRI as a reduction of 35% or more
in lumbar incapacity as reported on the Roland-Morris
Questionnaire (RMQ) [30].
The  secondary  result measures are: CRI at 12 and 48
weeks after randomisation and a series of result measures
(pain intensity, improvement perceived by the patient,
incapacity to work, quality of life (EuroQol 5D) and con-
sumption of analgesics) used to reflect the multidimen-
sional nature of the impact of low back pain, obtained at
3, 12 and 48 weeks after beginning the treatment. Other
secondary measures to be used are: a control scale of the
credibility of the treatment after the first week of treat-
ment, for Groups A, B and C, the pain intensity before and
immediately after each of the treatment sessions, the
record of the collateral effects and adverse reactions that
may appear up to week 3 (during the treatment phase),
the number of new episodes of low back pain reported atBMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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weeks 12 and 48, and the number of days' enforced
absence from work because of low back pain from the
date of final assessment to weeks 12 and 48.
Roland-Morris Questionnaire on Lumbar Incapacity (RMQ): primary 
result variable, clinical relevant improvement (CRI)
The validity of the Spanish version of the RMQ has been
confirmed independently [31]. It consists of 24 pages
related to the incapacity provoked by low back pain. The
patients must mark each question according to whether
they consider it may be applicable to their case or their
current state (on the day when the questionnaire is filled
in). Scoring the questionnaire is fast and straightforward:
each question marked is scored one point, and so the
accumulated points range from zero (no incapacity
caused by low back pain) to 24 (maximum possible inca-
pacity) [32]. This continuous variable will be recoded into
a binary variable in order to determine whether CRI has
been achieved. The following binary values will be
adopted: (0) = Improvement (reduction of 35% or more
on the RMQ [30]); (1) = Reduction of less than 35% on
the RMQ).
Pain intensity, according to a visual analogue scale (painVAS)
There exists ample evidence for the validity of the visual
analogue scale (VAS) of pain intensity. Many studies have
shown the validity of the construct [33] and its reliability
[34,35]. This is a fast and straightforward method of eval-
uating the subjective intensity of pain. The patient is asked
to mark, on a millimetric scale from zero (absence of
pain) to 100 (the worst pain imaginable), the degree of
intensity of low back pain, both at rest (painVAS-r) and in
movement (painVAS-m) experienced on the day the
assessment is performed. Data have been obtained show-
ing that reductions of more than 35 mm are associated
with patients' sensations of improvement [18].
Questionnaire on Fear and avoidance beliefs arising from low back 
pain (FABQ)
This is the Spanish version of a questionnaire [36]
designed to evaluate attitudes of fear and avoidance that
are provoked by patients' beliefs concerning the origin
and risks of their low back pain. It consists of 16 items
divided into two subscales. The first five items assess feel-
ings and attitudes towards physical activity, and the
remaining 11 concern the situation with respect to work
[37]. The items are measured on a 7-point Likert-type
scale, ranging from 0 (total disagreement) to 6 (total
agreement), with the final range of possible values extend-
ing from zero to 96. The higher the value recorded, the
higher the degree of fear and avoidance conduct caused by
low back pain. A high degree of reliability has been
reported for the FABQ applied to patients suffering acute
low back pain [38,39].
Improvement perceived by the patient (IPP)
A Likert-type scale of 7 points is recommended for evalu-
ating the improvement perceived by the patient with non-
specific low back pain [40], but opinions differ concern-
ing the categories to be used. We have opted for the model
proposed by Hudak and Wright [41]:
"How satisfied are you with the results of your recent
treatment for low back pain?
1 = Extremely satisfied
2 = Very satisfied
3 = Moderately satisfied
4 = Indifferent (an approximately equal degree of satisfac-
tion and dissatisfaction)
5 = Moderately dissatisfied
6 = Very dissatisfied
7 = Extremely dissatisfied.
EuroQol 5-Dimension (EQ-5D)
This is a generic questionnaire, the validity of which has
been confirmed in Spain [42], that measures the quality of
life as regards personal health. It consists of two parts: in
the first, the patient evaluates in a descriptive way his/her
health state, with respect to five dimensions, namely
mobility, personal care, daily activities, pain/discomfort
and anxiety/depression. Each dimension is scored from
one to three, and so the best possible health profile is
11111 and the worst is 33333. In the second part, the
patient marks on a VAS from zero (the worst imaginable
state of health) to 100 (the best imaginable state of
health) his/her overall state of health on the day the ques-
tionnaire is completed. The two scores are complemen-
tary. EQ-5D has an index of reference values of possible
health profiles ranging from a value of one (the best state
of health) to zero (death). Thus, we seek to combine these
results with the years of life in order to calculate the years
of life adjusted for health-related quality of life [43-45]. By
this approach, as well as analysing cost-effectiveness, we
hope to carry out a cost-utility analysis.
Consumption of analgesics (CA)
Analgesic medication and NSAIDs consumed (whether or
not prescribed by the patient's doctor), scored on a 5-
point Likert scale: 0 = none; 1 = less than the normal
amount; 2 = daily, at the normal dose; 3 = higher than the
normal dose; 4 = in addition to that prescribed, the con-
sumption of other medication. The names and daily dosesBMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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of the pharmaceutical preparations consumed by the
patient will be recorded.
Control of the placebo (credibility)
▪ Expectation and Treatment Credibility Scale (ETCS)
[46]. This scale was first proposed by Borkovec and Nau
[47] and includes four items to be valued on a continuous
VAS of 0–10 (0 = totally disagree; 10 = totally agree): (1) I
am confident this treatment will alleviate my pain; (2) I
consider the treatment a logical one; (3) I would recom-
mend this treatment to a friend or relative suffering the
same complaint; (4) I believe this treatment would be an
option to consider for treating other problems. This eval-
uation will be made after the second treatment session,
among Groups A, B and C.
▪ Verification of the blinding, with respect to the patient
[28]. After the final treatment session for Groups A, B and
C, the patients will be asked, "Which treatment do you
think you have been given?" The possible answers are: 1 =
Real acupuncture; 2 = Sham or placebo acupuncture; 3 =
Not sure.
Collateral effects and adverse reactions (CEAR)
Possible collateral effects and adverse reactions that may
arise as a result of the treatment will be recorded.
Sociodemographic variables
The following sociodemographic variables will be
recorded: date of birth, sex, marital status (living alone or
cohabiting), educational level (no schooling/primary/sec-
ondary/university education) and intensity of physical
activity at work (high/moderate/sedentary). The level of
activity is classified according to risk factors such as the
movement or lifting of heavy weights, body posture
involving ventral flexing of the spinal column by 45° with
the knees unbent, and work with vibratory machinery; if
one of these factors is present during more than 50% of
the working day, the level of physical activity is considered
high; less than 50% is considered moderate and if it is
absent, the work is classed as sedentary [6].
Variables concerning the severity of the condition and work-related 
aspects
▪ The duration of absence from work is expressed as days
of absence because of the low back pain recognised at the
baseline assessment. As a secondary result measure, we
shall quantify the duration of transitory incapacity for
work caused by low back pain, from the start of the treat-
ment until the 12 and 48-week assessments [18].
▪ Low back pain related to occupational activity (common
occurrence or work-related occurrence: Do you think your
episode of low back pain is directly related to your work
activity) (Yes/No)
▪ The patients will also be asked about their degree of sat-
isfaction with their work, according to a 7-point Likert
scale, ranging from zero to six, as follows: 0 = very dissat-
isfied; 1 = moderately dissatisfied; 2 = a little dissatisfied;
3 = indifferent; 4 = a little satisfied; 6 = very satisfied.
▪ Duration of the present condition of low back pain (in
days).
▪ We will also examine whether there is a sensation of irra-
diated pain; and if so, whether this extends beyond the
knee.
▪ The consumption of healthcare resources from the onset
of the low back pain (number of times treated by his/her
GP, number of times treated at the hospital's emergency
department, number of times treated by a specialist, by a
private doctor or by a company doctor).
▪ Previous episodes. Patients will be asked, "With respect
to the acute low back pain you are presently suffering, is
this the first occurrence? (Yes/No). If not, please answer
the following:
• How many episodes of low back pain have you had dur-
ing the last two years?
• How long (in weeks) have you been off work because of
your back pain, during the last two years?"
Characteristic diagnostic variables, according to traditional Chinese 
medicine (TCM)
The doctor participating in the study should examine the
patient's clinical characteristics in order to make a diagno-
sis on the basis of which points can be selected for the
treatment of acute low back pain. Although these proce-
dure is only of use for the individuals included in Group
A, it will be carried out for all the patients involved in the
study.
Estimate of direct tangible costs
To estimate the costs of the different approaches to treat-
ment (i.e. acupuncture vs. conventional treatment), we
shall make a chart of the activities carried out, measure the
costs of each and identify areas of difference. The activities
will be evaluated according to the Activity Based Costing
(ABC) approach, under which each activity consumes
resources (inputs), related to personnel, work-absence,
material and pharmaceutical costs, in order to produce
results (outputs). These activities will be valued on a uni-
tary basis. The cost of each therapeutic intervention is
defined as the sum of the costs of each of the activities of
which it is constituted. Thus, we will be able to achieve a
much more accurate view of the cost of each of the inter-
ventions with respect to the other, and can therefore studyBMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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its impact during the follow-up sub-process and in future
studies. The cost components of the activities that are con-
sidered and the criteria for their economic evaluation are
as follows:
▪  Personnel: this covers the consumption of human
resources as a result of the development of the different
activities. This evaluation includes the cost per hour of
each category of professional. The cost will be estimated
taking into account the data provided by the Andalusian
Public Health System (SSPA).
▪ Work absence: We shall quantify the costs arising from
temporary occupational incapacity, depending on the
type of incident. The number of health-related absences
from work from the start of the study until the final fol-
low-up evaluation will be recorded, as will the number of
days off work during each such absence.
▪ Materials: This includes the consumption of materials
during the treatment process. Each material cost will be
evaluated at the price stated in the catalogue of the clinic's
stores office/Hospital supply division/Health District.
▪ Pharmaceutical costs: We will assess the costs of the dif-
ferent pharmaceutical products (number and unit cost),
on the basis of the prevailing retail prices.
Data records and analysis
Data records
A referral form has been created, to be filled in by the GP
requesting the inclusion in the study of patients who meet
the selection criteria. We will design a database for the
electronic storage of the data recorded in the paper-format
Data Record Book (DRB) kept for this purpose. This data-
base will remain at the analysis centre (Research Support
Unit, Costa del Sol Hospital, Marbella, Málaga), which
will be independent of the randomisation centre. Each
participating clinic will have a replica of the structure of
this database (DRB-Rep) and a codebook with the defini-
tions and operational characteristics of all the variables.
The information will be recorded in a general question-
naire that covers each and every one of the variables con-
sidered in the study, both for the self-administered
formats and in those obtained by direct observation.
These data will be recorded on a daily basis in the DRB-
Rep and sent (encoded) to the analysis centre once
weekly, to ensure their safety. Neither the DRB nor the
DRB-Rep will state which group a patient has been
assigned to. The assignment to the different study groups
will be known to the doctors who perform the corre-
sponding treatments, and who is responsible for commu-
nication with the randomisation centre. Every two weeks,
the analysis centre will carry out a quality control exercise
on the data received.
Statistical analysis
The analysis will be carried out for two types of popula-
tion: (1) intention to treat (ITT) for all the randomised
patients; (2) per protocol (PP), including only those
patients with minor deviations from the protocol. All the
demographic, clinical and baseline result-variable data
will be analysed descriptively, using means and standard
deviations for the continuous variables and percentages
for the categoric ones, performed separately for each treat-
ment group.
The verification of the principle result variable and all the
principle analyses will be based on the ITT population.
For the principal objective, the null hypothesis to be veri-
fied will be that real acupuncture = conventional treat-
ment.
The two-tailed level of significance used will be α<0.05.
To adjust for possible confounders and to detect potential
interactions with the "treatment group" variable, logistic
regression models will be constructed, adjusted for the
baseline level. These models will include the variables of
the group and the baseline variables, as well as sociode-
mographic data (age and sex) and of the baseline severity
of the complaint (RMQ, painVAS, EQ-5D, CA, FABQ,
level of physical activity, duration of time off work), using
criteria of statistical significance and of confusion (assum-
ing a change of greater than 10% in the Odds Ratio of the
"treatment group" variable). The model will be recon-
structed removing the observations with Cook distances
greater than the 90 percentile of the distribution, in order
to test the consistency of the results. A Kaplan-Meier sur-
vival analysis will be performed to evaluate the number of
work days lost from the start of the study until the return
to normal work activity, using the corresponding Cox's
regression model of proportional risks to control for con-
founders.
Finally, a Bayesian analysis will be carried out on the CRI,
principal result variable. This latter analysis is aimed at
complementing the conventional analysis with a new
approach that could provide interesting additional
results. To achieve this, we will construct a distribution of
differences in proportions, by simulation [48,49]. First,
the a priori distribution is fixed for each of the recovery or
success percentages, based on the results available in rela-
tion to the treatment in question, the fundamental source
for this approach being the studies by Haake et al. [23]and
by Grotle et al. [5]. To define the respective a priori distri-
butions (the beta distributions), we shall estimate the fre-
quentist (conventional) confidence intervals associated
with these prior data. We shall then choose the (alpha and
beta) parameters such that the intervals of maximum den-
sity of these distributions will approximately coincide
with the confidence intervals obtained by the above-men-BMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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tioned authors. We shall use the success rates observed in
the present study, in the follow up at three months after
the start, for each of the experimental and control groups
(for each of the comparisons) in order to update the a pri-
ori information, using Bayesian theory. Ten thousand sim-
ulations will be performed to obtain the a posteriori
empirical distribution of the difference in proportions of
success (experimental minus conventional). When we
have this distribution, it will be possible to make a non-
parametric estimation of the probability of the experi-
mental procedure surpassing the conventional one by at
least 10%, and to obtain a suitable confidence interval.
Data analysis will be performed using the SPSS v10.5 soft-
ware package, while the statistical program Epidat 3.0 will
be used for the Bayesian analysis.
We intend to carry out a cost-effectiveness analysis; to
achieve this, a decision-making tree will be constructed,
based on the analysis of data obtained from this clinical
trial. It will be presented with a decision-node box in
which the choice of one path or another will be in the
hands of the medical professional. A circle will contain
the probabilistic nodes, in which situations occur with a
given probability and cannot be influenced by the clinic.
The terminal nodes represent the end of each of the ther-
apeutic decisions, for which a double evaluation will be
made: on the one hand, the effectiveness of the treatment
for acute low back pain and, on the other, the direct tan-
gible cost of the therapeutic activities considered.
By comparing the results obtained by means of each
approach, we can calculate the cost, the marginal cost, the
effectiveness and the marginal effectiveness. Finally, we
will calculate the marginal cost-effectiveness parameter, as
follows: (Cost of approach B - Cost of approach A)/(Effec-
tiveness of approach B - Effectiveness of approach A).
A sensitivity analysis will be carried out, by which we shall
obtain the results for the different outset hypotheses,
changing the values of the variables or critical factors that
present uncertainty. The different therapeutic approaches
can be studied by means of an incremental analysis, con-
sisting of dividing the increased cost of a given approach
by the increased effectiveness achieved. All the analyses
will be made without revealing the blinding of the differ-
ent branches of the study.
Sample size
We decided to use a sample size of n = 70 patients in each
group. This is the approximate size produced by accepting
a probability of 0.05 of committing a type I error, assum-
ing a power of 80% and a ratio of group A/Group D = 1,
with a CRI success rate of 85% for Group A (true acupunc-
ture) and of 63% for Group D (conventional treatment).
These percentages were taken from the results of a prior
pilot experiment, carried out from October to December
2004 at the Dos Hermanas health centre, after two weeks'
treatment (unpublished data). We assume a possible
dropout rate of 20%. The overall size of the sample will be
n = 336 (84 in each group).
Current status of the trial
Recruiting of the patients began in February 2006 and will
continue until December 2006. Follow up is planned to
end in January 2008.
Discussion
Various excellent studies have analysed the effects of acu-
puncture on chronic acute low back pain, for example
Brinkhaus et al. [50]. Nevertheless, rigorous studies have
yet to be made to evaluate the efficacy of acupuncture
against acute low back pain. Clinical experience has
shown that uncomplicated lumbalgia responds rapidly to
acupuncture, which achieves a reduction in pain intensity
and duration, and also contributes to the prompt return of
patients to their normal working activity.
The standardised treatments used in RCT have been criti-
cised as not reflecting normal clinical practice [51], espe-
cially in view of the large variety of styles implemented in
the West. Although acupuncture treatment is usually indi-
vidualised, it depends to a large extent on the pathological
process identified by the physician; a good diagnosis is
essential in order to identify underlying patterns and to
choose the most appropriate treatment. The standard pat-
tern found in cases of non-specific acute low back pain is
that known in TCM as Qi stagnation and blood stasis (qi
zhi xue yu), although this may be associated with other
fundamental disorders such as Impediment pattern (bi
zheng) or Kidney qi vacuity (shen qi xu), among others. The
choice of acupuncture points for the study group treated
with genuine acupuncture was based on 'distance punc-
ture', taking into consideration the standard categories of
acute low back pain according to TCM. The doctors partic-
ipating in the project were free to select up to 4 points, but
were required to justify their decision. Another important
consideration is the use of 'dynamic puncture' (xingzhen),
which in most cases facilitates immediate analgesia.
We chose to include in the study a non-treated group, in
order to observe the normal evolution of the problem, the
Hawthorn effect and the trend towards the mean. The
group that was given placebo acupuncture, completely
inert, served to isolate the non-specific effects of acupunc-
ture treatment; this group received the same number of
sessions as did the experimental group, the same evalua-
tion procedure, the same physical contact and the impres-
sion of having received real acupuncture treatment. The
group given false acupuncture (i.e. at non-specific points),
on the other hand, served to detect the non-specific effectsBMC Complementary and Alternative Medicine 2006, 6:14 http://www.biomedcentral.com/1472-6882/6/14
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of the puncture, as any stimulus caused by a needle pene-
trating the skin may be capable of activating spinal nocic-
eptive neurons and sending an excitatory message to the
brain centres, thus causing a non-specific analgesic effect,
due to the activation of the pain-suppression system in the
spinal cords (diffuse noxious inhibitory controls [26,52-
54], among other effects. By definition, a placebo must be
inert, and so the method adopted (with no penetration of
the skin), we believe, is the most valid one.
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